These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28807039)

  • 21. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.
    Packnett ER; Winer IH; Oladapo A; Wojdyla M
    Hum Vaccin Immunother; 2023 Aug; 19(2):2252289. PubMed ID: 37828711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS).
    Fergie J; Suh M; Jiang X; Fryzek JP; Gonzales T
    J Infect Dis; 2022 Apr; 225(7):1197-1204. PubMed ID: 32691037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
    Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Respiratory syncytial virus risk factors in late preterm infants.
    Lanari M; Silvestri M; Rossi GA
    J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():102-7. PubMed ID: 19925369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing of two different epidemic seasons of bronchiolitis.
    Picone S; Fabiano A; Roma D; Paolillo P
    Ital J Pediatr; 2018 Jan; 44(1):11. PubMed ID: 29338779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eligibility for palivizumab prophylaxis in a cohort of children with severe bronchiolitis.
    Hasegawa K; Mansbach JM; Piedra PA; Dunn MB; Clark S; Sullivan AF; Camargo CA
    Pediatr Int; 2015 Oct; 57(5):1031-4. PubMed ID: 26508190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association Between Updated Guideline-Based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections.
    Grindeland CJ; Mauriello CT; Leedahl DD; Richter LM; Meyer AC
    Pediatr Infect Dis J; 2016 Jul; 35(7):728-32. PubMed ID: 27078122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Palivizumab administration in preterm infants in France: EPIPAGE-2 cohort study.
    Torchin H; Rousseau J; Marchand-Martin L; Truffert P; Jarreau PH; Ancel PY
    Arch Pediatr; 2018 Feb; 25(2):89-94. PubMed ID: 29395887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Respiratory syncytial virus bronchiolitis in congenital diaphragmatic hernia: A systematic review of prevalence rates and palivizumab prophylaxis.
    Lewis L; Sinha I; Losty PD
    Pediatr Pulmonol; 2022 Jan; 57(1):239-244. PubMed ID: 34617409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Palivizumab's real-world effectiveness: a population-based study in Ontario, Canada, 1993-2017.
    Fitzpatrick T; McNally JD; Stukel TA; Kwong JC; Wilton AS; Fisman D; Guttmann A
    Arch Dis Child; 2021 Feb; 106(2):173-179. PubMed ID: 32859612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T; Rozé JC; Fauroux B;
    Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of Palivizumab against Respiratory Syncytial Virus: Cohort and Case Series Analysis.
    Moore HC; de Klerk N; Richmond PC; Fathima P; Xu R; Keil AD; Snelling TL; Strunk T
    J Pediatr; 2019 Nov; 214():121-127.e1. PubMed ID: 31378522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of respiratory syncytial virus bronchiolitis in hospitalized infants born at 33-36 weeks of gestational age compared with those born at term: a retrospective cohort study.
    Greenberg D; Dagan R; Shany E; Ben-Shimol S; Givon-Lavi N
    Clin Microbiol Infect; 2020 Feb; 26(2):256.e1-256.e5. PubMed ID: 31181285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention.
    Manzoni P; Paes B; Resch B; Carbonell-Estrany X; Bont L
    Early Hum Dev; 2012 May; 88 Suppl 2():S34-41. PubMed ID: 22633511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.
    Mahadevia PJ; Masaquel AS; Polak MJ; Weiner LB
    J Med Econ; 2012; 15(5):987-96. PubMed ID: 22574798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
    Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
    South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Observed Effectiveness of Palivizumab for 29-36-Week Gestation Infants.
    Farber HJ; Buckwold FJ; Lachman B; Simpson JS; Buck E; Arun M; Valadez AM; Ruiz T; Alonzo J; Henry A; Cos-Okpalla N; Nguyen K; Brendel W; Small J; Glomb WB
    Pediatrics; 2016 Aug; 138(2):. PubMed ID: 27432850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Impact of a targeted educational intervention on respiratory syncytial virus bronchiolitis prevention in full-term and preterm infants].
    Bernard L; Lecomte B; Pereira B; Proux A; Boyer A; Sautou V
    Arch Pediatr; 2015 Feb; 22(2):146-53. PubMed ID: 25534557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for respiratory syncytial virus bronchiolitis hospitalizations in children with chronic diseases.
    Shmueli E; Goldberg O; Mei-Zahav M; Stafler P; Bar-On O; Levine H; Steuer G; Mussaffi H; Gendler Y; Blau H; Prais D
    Pediatr Pulmonol; 2021 Jul; 56(7):2204-2211. PubMed ID: 33913611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.